GHK-CU
50 mgThe Element ResearchCOAs available · Purity > 98%
Limited stock
44.99 €View details →
Due to high order volume, shipments resume from 25 June. For any GLP-3 or GHK-Cu purchase, a complimentary GHK-Cu 50 mg vial is added automatically once payment is confirmed.
Lyophilized research compound
GLP-3 RTA pour recherche
In-vitro research reagent. Not for human or veterinary consumption.
Third-party testing · COAs availableTracked EU shippingCard or bank transfer
Ce produit est destiné exclusivement à la recherche scientifique in vitro et préclinique. Il n'est pas approuvé pour un usage humain ou vétérinaire.
Reconstitution guide
Dosages, protocols and storage per peptide.
Vial format
5 mgout of stock10 mgout of stock20 mgout of stock
Reconstitution solvent
BACT-H2O · 10 ml USP
+15 €
1
Total
135 €
Shipping from 25 June (high demand).
COAs availablePurity > 98%Shipping 24–48hProtective packagingCard & bank transfer
Trustpilot
This lyophilized peptide is intended for in-vitro and preclinical research. It is formulated to provide stability and purity suited to advanced research protocols. Not for direct human or veterinary consumption.
The Element Research peptides are selected for their long-term stability and compatibility with demanding research protocols. Lyophilization ensures optimal storage before reconstitution.
Mechanism of action
Triple action synergy
GLP-3 RTA 20MG is the first molecule to activate 3 hormonal receptors simultaneously, whereas semaglutide activates only one.
GLP-101Appetite control
Slows gastric emptying, increases satiety and reduces food intake. Acts on brain hunger receptors (hypothalamus).
GLP-1R receptor
GIP02Insulin sensitivity
Optimizes post-prandial insulin response and promotes controlled lipid storage, complementing the GLP-1 axis on glycemia.
GIPR receptor
Glucagon03Energy expenditure
Stimulates hepatic lipolysis and thermogenesis. Increases resting energy expenditure, the key differentiator vs other GLP-1s.
GCGR receptor
GLP-3 RTA 20MG activates all 3 simultaneously. Semaglutide (Ozempic) only activates GLP-1. Tirzepatide (Mounjaro) activates GLP-1 + GIP. GLP-3 RTA 20MG is the only one to also activate the Glucagon receptor, the source of its superiority in energy expenditure.
Related products
Complete your research protocol with these compounds.
